Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(butylamino)propan-2-yl)phosphinic Acid
2. Butaphosphan
1. 17316-67-5
2. Butaphosphan
3. 2-(butylamino)propan-2-yl-hydroxy-oxophosphanium
4. [2-(butylamino)propan-2-yl]phosphinic Acid
5. Phosphinic Acid, [1-(butylamino)-1-methylethyl]-
6. 1-(butylamino)-1-methylethyl]-phosphonic Acid
7. 3q2lq1149l
8. Ncgc00249608-01
9. 2-(butylamino)propan-2-ylphosphinic Acid
10. (1-(butylamino)-1-methylethyl)phosphinic Acid
11. Butafosfano
12. Butafosfanum
13. 1-(butylamino)-1-methylethyl)-phosphonic Acid
14. Butafosfan [inn:ban]
15. Sr-01000945191
16. Butafosfanum [inn-latin]
17. Butafosfano [inn-spanish]
18. Butapho
19. Unii-3q2lq1149l
20. Einecs 241-341-7
21. 1-(buylamino-1-methyl)ethylphosphinsaeure
22. Butafosfan [inn]
23. Dsstox_cid_28607
24. Dsstox_rid_82877
25. Dsstox_gsid_48681
26. Schembl2110672
27. Chembl1979022
28. Dtxsid5048681
29. Dtxsid00860202
30. Bcp12944
31. Tox21_113065
32. Mfcd00869071
33. Stl135983
34. Zinc38322248
35. Zinc95913251
36. Akos005746929
37. Akos015918370
38. Ncgc00249608-02
39. As-15854
40. 2-(butylamino)propan-2-yl)phosphinic Acid
41. Cas-17316-67-5
42. Ft-0623297
43. [1-(butylamino)-1-methyl-ethyl]phosphinic Acid
44. 316b675
45. A811490
46. Phosphinic Acid, (1-(butylamino)-1-methyethyl)-
47. J-010881
48. Sr-01000945191-1
49. Sr-01000945191-2
50. (2-(butylamino)propan-2-yl)(hydroxy)(oxo)phosphonium
51. Phosphinic Acid, P-[1-(butylamino)-1-methylethyl]-
52. Q27257890
53. 1-( N-butylamino)-1-methylethyl Phosphonous Acid
Molecular Weight | 178.19 g/mol |
---|---|
Molecular Formula | C7H17NO2P+ |
XLogP3 | 0.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 5 |
Exact Mass | 178.09969078 g/mol |
Monoisotopic Mass | 178.09969078 g/mol |
Topological Polar Surface Area | 49.3 Ų |
Heavy Atom Count | 11 |
Formal Charge | 1 |
Complexity | 136 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Market Place
ABOUT THIS PAGE
A Butafosfan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Butafosfan, including repackagers and relabelers. The FDA regulates Butafosfan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Butafosfan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Butafosfan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Butafosfan supplier is an individual or a company that provides Butafosfan active pharmaceutical ingredient (API) or Butafosfan finished formulations upon request. The Butafosfan suppliers may include Butafosfan API manufacturers, exporters, distributors and traders.
click here to find a list of Butafosfan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Butafosfan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Butafosfan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Butafosfan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Butafosfan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Butafosfan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Butafosfan suppliers with NDC on PharmaCompass.
Butafosfan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Butafosfan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Butafosfan GMP manufacturer or Butafosfan GMP API supplier for your needs.
A Butafosfan CoA (Certificate of Analysis) is a formal document that attests to Butafosfan's compliance with Butafosfan specifications and serves as a tool for batch-level quality control.
Butafosfan CoA mostly includes findings from lab analyses of a specific batch. For each Butafosfan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Butafosfan may be tested according to a variety of international standards, such as European Pharmacopoeia (Butafosfan EP), Butafosfan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Butafosfan USP).
LOOKING FOR A SUPPLIER?